pcn poster

Posters

Interim Analysis of a Patient-Reported Impact Measure in the IMPACT-TD Registry

Abstract: Background: The IMPACT-TD Patient Reported Outcome (IMPACT-TD PRO) scale is a newly developed patient questionnaire to assess the multidimensional impact of tardive dyskinesia (...

08/20/2024

Isolated Hyper-religiosity in Patient after Resection of Sphenoidal Meningioma: A Case Report

Abstract: A 57-year-old female patient with a known history of left frontotemporal meningioma presented to the emergency room with visual and auditory hallucinations and hyper-religiosity...

08/20/2024

Evaluation of AXS-05 (dextromethorphan-bupropion) in Major Depressive Disorder Using the Interest-Activity Domain

Abstract: Background: Individuals with major depressive disorder (MDD) with loss of interest and reduced activity respond poorly to serotonergic antidepressants. AXS-05 (dextromethorphan-...

08/20/2024

Latent Variable Analysis of Antipsychotic Adherence among South Carolina Medicaid Beneficiaries with Schizophrenia

Abstract: Schizophrenia, a chronic mental illness, requires long-term treatment with antipsychotics, where adherence is crucial for favorable clinical and economic outcomes. Adherence, ho...

08/20/2024

Experiences and Perceptions of Psychiatrists Treating Schizophrenia With Long-Acting Injectable Antipsychotics: Qualitative Results From the Multinational ADVANCE Study

Abstract: Background: Psychiatrists’ views on schizophrenia treatment goals and use of long-acting injectable antipsychotics (LAIs) vary widely.

08/20/2024

Formation of a working alliance and potential efficacy of a digital therapeutic to treat experiential negative symptoms of schizophrenia

Abstract: Introduction: Currently, no FDA-approved pharmacological treatments satisfactorily address experiential negative symptoms (ENS) of schizophrenia. CT-155 is a prescription digita...

08/20/2024

Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder

Abstract: Background: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. In real...

08/20/2024

Healthcare Resource Utilization in Patients With Tardive Dyskinesia Treated With Benztropine Compared With a Non-Treated Cohort

Abstract: Background: Benztropine may be prescribed off-label to patients with tardive dyskinesia (TD) to provide symptom relief; however, per benztropine prescribing information, it may ...

08/20/2024

How Patients with Depression and their Providers Navigate Anhedonia: An Ethnographic Evaluation of Discourse Dynamics of Psychiatrists and Primary Care Providers in Clinical Settings

Abstract: Background Anhedonia, a key symptom of major depressive disorder (MDD), impacts patients' quality of life and treatment outcomes. However, limited research exists on healthcare ...

08/20/2024

Hybrid Approach to Development of a Patient-Reported Outcomes (PRO) Instrument to Assess the Impact of Tardive Dyskinesia (IMPACT-TD PRO) in Adults

Abstract: Background: Patient-reported outcomes (PROs) are important for assessing disease burden. Specific measures characterizing the multidimensional impact of tardive dyskinesia (TD) ...

08/20/2024

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products